

PAT. NO.	Title
1	10,614,284 T Descriptive measurements and quantification of staining artifacts for in situ hybridization
2	10,610,584 T Reverse genetics systems
3	10,597,736 T Compositions and methods for detecting viruses in a sample
4	10,597,380 T Pyridazinone-based broad spectrum anti-influenza inhibitors
5	10,590,173 T Picornavirus-like particle production in plants
6	10,562,936 T Ligands for integrin .alpha.v.beta.6, synthesis and uses thereof
7	10,532,111 T Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
8	10,532,066 T Surfactant lipids, compositions thereof, and uses thereof
9	10,493,145 T Immunogenic rhinovirus peptides
10	10,478,444 T Methods and compositions for treating and preventing viral infections
11	10,472,667 T Method for fragmenting and ligating adapters onto a nucleic acid and kit for performing the same
12	10,450,320 T Hexahydropyrazinotriazinone derivatives as kinase inhibitors
13	10,434,116 T Methods of treating coronavirus infection
14	10,421,999 T Targeted sequencing and UID filtering
15	10,421,749 T Pyrone derivatives for use as antiviral agents
16	10,407,429 T Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
17	10,385,320 T Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
18	10,370,401 T Substituted nucleosides, nucleotides and analogs thereof
19	10,363,282 T Analogues of C5a and methods of using same
20	10,344,320 T Capacitive liquid crystal biosensors
21	10,316,372 T Molecular detection of enterovirus and parechovirus
22	10,307,374 T Oil-in-water emulsions that contain nucleic acids
23	10,300,127 T Immune complex
24	10,294,534 T Respiratory infection assay
25	10,293,014 T Immune stimulating composition comprising an extract of Aronia sp. in combination with selenium and/or zinc

- 26 [10,253,375](#) **T** [Massively parallel single cell analysis](#)
- 27 [10,253,300](#) **T** [Adapted rhinovirus C](#)
- 28 [10,238,733](#) **T** [Cationic oil-in-water emulsions](#)
- 29 [10,238,682](#) **T** [Structure and use of 5' phosphate oligonucleotides](#)
- 30 [10,226,449](#) **T** [Heterocyclic modulators of lipid synthesis and combinations thereof](#)
- 31 [10,220,002](#) **T** [Controlled-release peptide compositions and uses thereof](#)
- 32 [10,208,356](#) **T** [Massively parallel single cell analysis](#)
- 33 [10,202,654](#) **T** [Methods for detecting Legionella nucleic acids in a sample](#)
- 34 [10,202,615](#) **T** [Mammalian genes involved in toxicity and infection](#)
- 35 [10,202,423](#) **T** [Picornavirus-like particle production in plants](#)
- 36 [10,189,822](#) **T** [Heterocyclic modulators of lipid synthesis](#)
- 37 [10,183,074](#) **T** [Cationic oil-in-water emulsions](#)
- 38 [10,179,176](#) **T** [Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies](#)
- 39 [10,151,003](#) **T** [Massively Parallel single cell analysis](#)
- 40 [10,149,859](#) **T** [Nucleotide and nucleoside therapeutic compositions and uses related thereto](#)
- 41 [10,131,958](#) **T** [Massively parallel single cell analysis](#)
- 42 [10,125,187](#) **T** [Antibodies specific for enteroviruses that infect humans](#)
- 43 [10,119,138](#) **T** [iRNA agents with biocleavable tethers](#)
- 44 [10,092,006](#) **T** [Stable compositions of uncomplexed iodine and methods of use](#)
- 45 [10,087,209](#) **T** [Antiviral compounds, a process for their preparation, and their use for treating viral infections](#)
- 46 [10,087,180](#) **T** [Pyrazolo-pyridine derivatives as kinase inhibitors](#)
- 47 [10,072,308](#) **T** [Molecular detection of enterovirus and parechovirus](#)
- 48 [10,072,305](#) **T** [Real-time PCR for the detection of pathogens](#)
- 49 [10,058,603](#) **T** [Vaccine](#)
- 50 [10,052,329](#) **T** [Viral prophylaxis treatment methods and pre-exposure prophylaxis kits](#)
- 51 [10,041,951](#) **T** [Imaging probe including nanoparticle](#)

- 52 [10,031,135](#) **T** [Detection of bioagents using a shear horizontal surface acoustic wave biosensor](#)
- 53 [10,031,134](#) **T** [Antibody-nanoparticle conjugates and methods for making and using such conjugates](#)
- 54 [10,026,599](#) **T** [Rapid evaporative ionisation mass spectrometry \("REIMS"\) and desorption electrospray ionisation mass spectrometry \("DESI-MS"\) analysis of swabs and biopsy samples](#)
- 55 [10,004,701](#) **T** [Methods and compositions for treating infection](#)
- 56 [10,000,497](#) **T** [Fused bicyclic heteroaromatic derivatives as kinase inhibitors](#)
- 57 [9,994,550](#) **T** [Heterocyclic modulators of lipid synthesis for use against cancer and viral infections](#)
- 58 [9,988,390](#) **T** [Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease](#)
- 59 [9,969,748](#) **T** [Fused bicyclic heteroaromatic derivatives as kinase inhibitors](#)
- 60 [9,963,455](#) **T** [Pyrazolo\[1,5-a\]pyrimidines as antiviral compounds](#)
- 61 [9,957,302](#) **T** [Treating cancer with viral nucleic acid](#)
- 62 [9,944,998](#) **T** [Genetic assays](#)
- 63 [9,938,588](#) **T** [Compositions and methods for detecting Enterovirus D68](#)
- 64 [9,920,355](#) **T** [Method for fragmenting and ligating adaptors onto a nucleic acid, and kit for performing the same](#)
- 65 [9,920,128](#) **T** [Synthetic antiserum for rapid-turnaround therapies](#)
- 66 [9,909,176](#) **T** [Efficient deep sequencing and rapid genomic speciation of RNA viruses \(vRNAseq\)](#)
- 67 [9,895,411](#) **T** [Analogues of C5a and methods of using same](#)
- 68 [9,890,188](#) **T** [Substituted nucleosides, nucleotides and analogs thereof](#)
- 69 [9,885,082](#) **T** [Embodiments of a probe and method for targeting nucleic acids](#)
- 70 [9,872,875](#) **T** [Component and method for treating viral disease](#)
- 71 [9,867,835](#) **T** [Methods and compositions for treating and preventing viral infections](#)
- 72 [9,862,743](#) **T** [Substituted nucleosides, nucleotides and analogs thereof](#)
- 73 [9,861,649](#) **T** [Surfactant lipids, compositions thereof, and uses thereof](#)
- 74 [9,840,731](#) **T** [Preservation of biological materials in non-aqueous fluid media](#)
- 75 [9,827,244](#) **T** [Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease](#)
- 76 [9,821,052](#) **T** [Reverse genetics systems](#)

- 77 [9,809,591](#) **T** [Heterocyclic modulators of lipid synthesis](#)
- 78 [9,795,668](#) **T** [Delivery of self-replicating RNA using biodegradable polymer particles](#)
- 79 [9,730,944](#) **T** [Antiviral activity of novel bicyclic heterocycles](#)
- 80 [9,725,771](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 81 [9,714,248](#) **T** [Therapeutically active pyrazolo-pyrimidine derivatives](#)
- 82 [9,701,740](#) **T** [Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair](#)
- 83 [9,670,485](#) **T** [Partitioning of DNA sequencing libraries into host and microbial components](#)
- 84 [9,655,845](#) **T** [Oil-in-water emulsions that contain nucleic acids](#)
- 85 [9,650,685](#) **T** [Selective detection of human rhinovirus](#)
- 86 [9,637,799](#) **T** [Massively parallel single cell analysis](#)
- 87 [9,636,410](#) **T** [Cationic oil-in-water emulsions](#)
- 88 [9,630,957](#) **T** [2,3-butanediamide epoxide compound and preparation method and use thereof](#)
- 89 [9,624,173](#) **T** [Heterocyclic modulators of lipid synthesis](#)
- 90 [9,618,429](#) **T** [Polymer stabilization of chromogen solutions](#)
- 91 [9,598,736](#) **T** [Massively parallel single cell analysis](#)
- 92 [9,579,005](#) **T** [Portable hospital cleaning apparatus](#)
- 93 [9,567,646](#) **T** [Massively parallel single cell analysis](#)
- 94 [9,567,645](#) **T** [Massively parallel single cell analysis](#)
- 95 [9,518,303](#) **T** [Methods and compositions for identifying enterovirus](#)
- 96 [9,517,263](#) **T** [Benzonaphthyridine-containing vaccines](#)
- 97 [9,505,758](#) **T** [Substituted 1,5-naphthyridines as endonuclease inhibitors](#)
- 98 [9,476,045](#) **T** [iRNA agents with biocleavable tethers](#)
- 99 [9,447,132](#) **T** [Highly active nucleoside derivative for the treatment of HCV](#)
- 100 [9,442,107](#) **T** [Antibody-nanoparticle conjugates and methods for making and using such conjugates](#)
- 101 [9,435,795](#) **T** [Enhanced deposition of chromogens utilizing pyrimidine analogs](#)
- 102 [9,434,745](#) **T** [7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease](#)

- 103 [9,422,342](#) **T** [Recoding method that removes inhibitory sequences and improves HIV gene expression](#)
- 104 [9,416,424](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 105 [9,394,574](#) **T** [Methods for detecting Legionella nucleic acids in a sample](#)
- 106 [9,382,263](#) **T** [Therapeutically active oxazoline derivatives](#)
- 107 [9,381,208](#) **T** [Structure and use of 5' phosphate oligonucleotides](#)
- 108 [9,359,351](#) **T** [Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease](#)
- 109 [9,295,646](#) **T** [Cationic oil-in-water emulsions](#)
- 110 [9,284,560](#) **T** [Application of highly conserved domain sequences from viral genome as template to design therapeutic siRNAs](#)
- 111 [9,243,230](#) **T** [Construct for producing empty virus capsids](#)
- 112 [9,243,050](#) **T** [Stabilized immune modulatory RNA \(SIMRA\) compounds for TLR7 and TLR8](#)
- 113 [9,243,036](#) **T** [Anti-microbial activity of synthetic peptides](#)
- 114 [9,227,984](#) **T** [Therapeutically active fused pyrimidine derivatives](#)
- 115 [9,199,987](#) **T** [Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease](#)
- 116 [9,193,741](#) **T** [Antiviral activity of bicyclic heterocycles](#)
- 117 [9,192,661](#) **T** [Delivery of self-replicating RNA using biodegradable polymer particles](#)
- 118 [9,175,268](#) **T** [Methods for the production of iPS cells](#)
- 119 [9,145,585](#) **T** [Method for using permuted nucleic acid probes](#)
- 120 [9,127,028](#) **T** [Substrates for chromogenic detection and methods of use in detection assays and kits](#)
- 121 [9,096,614](#) **T** [Therapeutically active thiazolo-pyrimidine derivatives](#)
- 122 [9,085,641](#) **T** [Peptides regulating the surface expression of the T cell receptor](#)
- 123 [9,082,554](#) **T** [Biologically self-assembled nanotubes](#)
- 124 [9,080,142](#) **T** [Plant virus designated tomato marchitez virus](#)
- 125 [9,072,702](#) **T** [Reverse genetics using non-endogenous pol I promoters](#)
- 126 [9,045,486](#) **T** [Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease](#)
- 127 [9,040,310](#) **T** [Antibody-nanoparticle conjugates and methods for making and using such conjugates](#)
- 128 [9,023,345](#) **T** [Methods for improving gut health](#)

- 129 [9,011,821](#) **T** [PLA2G16 as a target for antiviral compounds](#)
- 130 [8,993,746](#) **T** [Nuclease resistant double-stranded ribonucleic acid](#)
- 131 [8,993,318](#) **T** [Pathogen restriction factors](#)
- 132 [8,987,306](#) **T** [Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold](#)
- 133 [8,986,999](#) **T** [Virus/nanowire encapsulation within polymer microgels for 2D and 3D devices for energy and electronics](#)
- 134 [8,986,933](#) **T** [Selective detection of human rhinovirus](#)
- 135 [8,980,545](#) **T** [Divergent picornavirus: cosavirus](#)
- 136 [8,962,580](#) **T** [Chemical modifications of monomers and oligonucleotides with cycloaddition](#)
- 137 [8,952,039](#) **T** [Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease](#)
- 138 [8,921,388](#) **T** [Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease](#)
- 139 [8,921,047](#) **T** [Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby](#)
- 140 [8,883,481](#) **T** [Reverse genetics methods for virus rescue](#)
- 141 [8,871,790](#) **T** [Heterocyclic modulators of lipid synthesis](#)
- 142 [8,871,442](#) **T** [Enhanced deposition of chromogens](#)
- 143 [8,865,677](#) **T** [iRNA agents with biocleavable tethers](#)
- 144 [8,828,659](#) **T** [Method for producing nucleic acid probes](#)
- 145 [8,822,156](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 146 [8,821,897](#) **T** [Viral adjuvants](#)
- 147 [8,815,503](#) **T** [Compositions and methods for immunostimulatory RNA oligonucleotides](#)
- 148 [8,796,423](#) **T** [Anti-TSG101 antibodies and their uses for treatment of viral infections](#)
- 149 [8,796,243](#) **T** [Surfactant lipids, compositions thereof, and uses thereof](#)
- 150 [8,759,310](#) **T** [Stabilized immune modulatory RNA \(SIMRA\) compounds for TLR7 and TLR8](#)